Innovations Archive - WISH

Amprologix

wish admin — Wed, 08 May 2024 09:56:37 +0000

Epidermicin is an exciting innovation that can be used to prevent and treat infections caused by hospital ‘superbugs’ like MRSA. This first in class antimicrobial demonstrated high efficiency in infection models: research showed that a single dose of Epidermicin is as active as six doses of current standard treatment. Epidermicin has very low levels of toxicity. It has recently completed pre-clinical evaluation with no adverse effects observed. Topical use of Epidermicin to treat skin and other types of infection, including pneumonia, could reduce the need for systemic antibiotics. This would improve antibiotic stewardship and help reduce antimicrobial resistance (AMR), a leading threat to global health. Epidermicin is manufactured using a highly cost-effective production method that meets regulatory requirements. The company is currently working on developing an AI-machine learning approach to generate novel variants of Epidermicin with activity ‘tuned’ towards different target bacteria. Epidermicin can become a leading agent in the prevention and treatment of devastating infections caused by bacteria high on the WHO list of priority pathogens.

The post Amprologix appeared first on WISH.

Goldilocks Suit PTY LTD

wish admin — Wed, 08 May 2024 09:54:25 +0000

Goldilocks is working at the forefront of early intervention and prevention – it uses smart clothing and AI to coach customers on how to stay in the Goldilocks zone – safe, happy and well. Goldilocks’ first product on the market looks like a standard baby singlet. However, screen-printed on the inside, are micro-sensors which monitor the baby’s biometrics and transmit them to a smart device. The Goldilocks app uses AI to understand the baby’s feeding, sleeping, breathing, skin and core temperature patterns. Thanks to a unique algorithm, this data is analyzed to define a personalized “normal” condition for each baby. When an irregularity is detected, Goldilocks alerts the parents and provides support from a clinician (if required). Goldilocks is more than just an alerting device. It continuously and holistically monitors the baby’s wellbeing and compares it to the baby’s ‘normal’ condition. Goldilocks also provides actionable insights to help parents resolve the underlying issue(s). The magic behind Goldilocks is that it provides parents with the most relevant, bite-sized bits of information exactly when needed. If a parent can’t resolve the issue, Goldilocks will connect them with a clinician who can provide further support via telehealth. Goldilocks’ second product is for the aged care sector.

The post Goldilocks Suit PTY LTD appeared first on WISH.

WeWalk

wish admin — Wed, 08 May 2024 09:53:15 +0000

WeWalk is a smart cane powered by AI. It was inspired by the personal experiences of its inventors, also suffering from visual impairment. The team behind WeWalk believes that technology has already changed every aspect of our daily life dramatically, it is time it revolutionizes the standard white cane impaired people have been using for nearly a century now! Backed by Microsoft, WeWALK uses advanced technology and AI to better understand how visually impaired people move, enhancing the user experience with revolutionary mobility features.

The post WeWalk appeared first on WISH.

Mimosa Diagnostics

wish admin — Wed, 08 May 2024 09:52:26 +0000

The MIMOSA platform is an FDA-cleared class II medical device. MIMOSA is designed for the early detection and preventative care of reperfusion injuries. Reperfusion injuries can appear in the case of peripheral vascular diseases, wounds, surgery and when the need for intensive care arises. There are no technologies that can truly assess these injuries. Current technologies are large, expensive, and not accessible to all patients. Therefore, specialized expertise is still required to physically examine patients. A delay in the diagnosis of reperfusion injuries results in wounds, amputations, and even death. The MIMOSA platform is a class II medical device. When paired with a smartphone, it relays the images to a web portal for remote viewing. MIMOSA brings technology to the patient, allowing him to take non-invasive images from which physiological insights can be extracted. These images are taken below the surface of the skin using novel biomarkers that are predictive of outcome. Thanks to machine learning, the device can function regardless of skin pigmentation and its portability makes expert care accessible across geographic borders. Over the last 6 months, MIMOSA was able to grow from 6 to 18 employees. It has also launched its early commercialization phase in the US. The size of the portable medical devices market is estimated to $85 Billion USD and MIMOSA’s model shows that the company can capture $200 Million in recurring annual revenue by 2025.

The post Mimosa Diagnostics appeared first on WISH.

ان هارت

wish admin — Wed, 08 May 2024 09:51:45 +0000

inHEART is committed to delivering the world’s most sophisticated, AI-enabled digital twin of the heart to advance the care of patients living with cardiac disease. The company believes that all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives. The inHEART solution targets physicians who are challenged with lengthy, complex, conventional ablation procedures with minimal insights into the detailed structural anatomy of their patient’s heart and how it may be driving the arrhythmia. The inHEART solution is the world’s most sophisticated 3D cardiac modeling software platform that leverages CT and MR images to deliver clear and precise maps of each patient’s unique cardiac anatomy, principal and collateral structures, and myocardial tissue characteristics to allow physicians to individualize and optimize each patient’s treatment strategy to improve efficiency and precision and support reduced procedure times and greater procedural success. The InHEART solution allows physicians to reduce procedure times by 60% and improve efficiency by 25%.

The post ان هارت appeared first on WISH.

ريلينك

wish admin — Wed, 08 May 2024 09:50:57 +0000

ReLink is an advanced breakaway connector, designed and engineered to prevent complications that occur during the administration of IV catheter such as dislodgement, occlusion, phlebitis and infiltration, providing increased safety for patients and nurses. Tada Group is a Swedish medical device company specialising in needs-based innovations for health and medical care. The company’s vision is to improve lives by providing innovative solutions for unmet healthcare needs. One such need is preventing IV catheter loss caused by dislodgement, occlusion, phlebitis and infiltration. ReLink, a market-ready breakaway connector, is a game changing device that helps to solve this global problem.

The post ريلينك appeared first on WISH.

سمايل ترونيكس

wish admin — Wed, 08 May 2024 09:49:13 +0000

Smiletronix is a home solution for dental checkup, tracking, and teledentistry. Smiletronix employs Ai to allow users to check their teeth from the comfort of their own homes using only a smart device and an app. By turning dental care from reactive to preventive, the company is working on reducing cost and pain, and improving access to care. It aims to revolutionize the management of dental care and benefits. Smiletronix is driven to employ technology in an area of healthcare that is often overlooked, yet vital to good health and wellbeing. Dental diseases are among the most prevalent untreated chronic diseases around the world, with untreated cavities ranking first and gum diseases ranking 6th. These numbers are due to a shortage in dental professionals, high costs, and accessibility problems in every country. Smiletronix can address all these issues. It combines health and wellness tracking, digital health, telehealth, and dentistry, all of which are rapidly growing. It answers to an increasing global demand for more accessible health and wellness solutions, tracking features, remote accessibility, and instant test results. Smiletronix aims to scale significantly over the upcoming months, bringing everybody a better and healthier smile.

The post سمايل ترونيكس appeared first on WISH.

العلاج التحفيزي لحديثي الولادة

wish admin — Mon, 06 May 2024 07:25:24 +0000

Apnea of Prematurity or AOP occurs when preterm newborns stop breathing for 20 seconds or longer. Repeated apneas decrease the oxygen level reaching vital organs leading to long-term neurodevelopmental issues. Approximately one in every ten babies is born premature, making AOP a global healthcare challenge. Caffeine is the most common treatment for AOP. Even though it was approved for use twenty-two years ago, it is only partially effective as most caffeinated babies continue to experience apneas for several days. Fortunately, clinicians and scientists discovered that ascending and descending vibrations moving within a small range and in low speed could help infants breathe. Clinical studies reported that preterm newborns lying on a uniquely vibrating mattress breathe better, have improved oxygenation, and maintain sleep cycles. This is due to the fact that vibrations boost neurons in the brain responsible for breathing and heart rate. In 2018, this technology was exclusively licensed by Prapela which develops reusable medical devices according to US and European regulatory standards. Prapela’s mission is to add a new capability to the thousands of incubators used around the world every day, replacing standard pads with Prapela’s innovation. More importantly, Prapela is introducing the first innovation to significantly improve the care for preterm newborns with AOP and the outcome of their condition in over twenty years.

The post العلاج التحفيزي لحديثي الولادة appeared first on WISH.

ركبة ريموتيون / جايبورفوت

wish admin — Mon, 04 Mar 2024 07:28:50 +0000

تجمع هذه المبادرة بين الابتكارات التكنولوجية والعملية لتوفير الأطراف الاصطناعية للأيدي والأقدام بتكلفة منخفضة في البلدان المتقدمة.

The post ركبة ريموتيون / جايبورفوت appeared first on WISH.

مركز هيليكس

wish admin — Mon, 04 Mar 2024 07:22:28 +0000

تُظهر هذه المبادرة بين الكلية الملكية للفنون وإمبريال كوليدج لندن نهجًا متعدد التخصصات حقيقيًا لمواجهة التحديات الصحية ، حيث تجمع بين خبرة التصميم والمعرفة السريرية لإنشاء حلول مبتكرة تناسب المرضى.

The post مركز هيليكس appeared first on WISH.